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Early & Periodic Screening, Diagnosis & Treatment
The Challenge of Detecting 
Prescription Opioid Abuse in Pregnancy
Matthew D. Krasowski, MD, PhD, 
Clinical Associate Professor of Pathology and Director of Clinical Laboratories 
University of Iowa Hospitals and Clinics
The last 10-15 years in the 
United States has seen a dra-
matic shift in prescription opioid 
abuse.1 Americans now con-
sume 80% of the world opioid 
supply despite constituting only 
4.6% of the world’s population. 
Hydrocodone (Vicodin®, Lortab®, 
etc.) is now the leading prescrip-
tion drug when all formula-
tions containing this opioid are 
summed together. Oxycodone 
(OxyContin®, Percocet®, etc.) has 
steadily increased in prescrip-
tions and is now in the top 20 
most prescribed medications 
in the United States. Fentanyl 
and methadone prescriptions 
increased approximately fivefold 
and tenfold, respectively, in the 
10 years from 1997-2007.
The increasing medical use of 
opioids has spawned greater 
availability of drugs that may 
get diverted and misused. Data 
from a variety of sources have 
documented increased over-
dose deaths, emergency room 
visits, and hospitalizations from 
prescription opioids. In 2007, 
opioids accounted for 11,500 
deaths in the United States, 
more than heroin and cocaine 
combined.1  
Abuse of prescription opioids 
in pregnancy is a concerning 
problem.2 Pregnant women 
may have access to medications 
from previous prescriptions, 
diversion from other people, or 
from prescriptions from non-
obstetric providers. Intrauter-
ine opioid exposure has been 
associated with intrauterine 
growth restriction, prematurity, 
and withdrawal symptoms. 
Neonatal abstinence syndrome 
in opioid-exposed infants can 
present with increased reflexes 
and muscle tone, abnormal 
sleeping and feeding patterns, 
diarrhea, vomiting, irritability, 
and high-pitched crying.
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Detecting Prescription Opioid Abuse in 
Pregnancy            (continued from page 1)
(continues on page 3)
Newborn Drug Screening
Due to the significant poten-
tial risk to the fetus and infant, 
timely detection of intrauterine 
drug exposure is paramount for 
peripartum and long-term clini-
cal management.2 Many institu-
tions have developed internal 
policies that include newborn 
drug screening in cases identi-
fied as high risk for maternal 
drug abuse (e.g., prior history 
of maternal drug abuse, signs 
of drug withdrawal in the new-
born). Drug testing may include 
mother or newborn or both.
The three main specimens used 
in newborn drug screening are 
urine (in mother and/or new-
born), meconium, and umbilical 
cord.3 Urine drug testing has 
a brief window of detection 
for drugs of abuse. In addition, 
specimen collection can be chal-
lenging in newborns. In new-
borns, urine testing only cap-
tures drug use close to the time 
of delivery—up to a few days 
(especially for most opioids), or 
at most a week. Urine drug test-
ing is unlikely to detect sporadic 
maternal drug abuse.
Meconium (infant’s first stool) be-
gins to form early in the second 
trimester and continues to ac-
cumulate throughout gestation. 
Meconium drug testing poten-
tially detects maternal drug use 
in the second and third trimes-
ters and has become the “gold 
standard” method for newborn 
drug screening.3 However, collec-
tion of meconium may be missed 
due to passage of meconium in 
utero prior to birth (especially in 
stressed fetuses), late passage 
after hospital discharge, or inad-
vertent or intentional disposal of 
diapers containing meconium. 
Drug abuse testing on umbili-
cal cord tissue is relatively new 
but shows similar length of 
detection window compared to 
meconium.3 Umbilical cord tis-
sue has the greatest ease of col-
lection, with collection possible 
in every infant. Unlike urine or 
meconium, umbilical cord will 
not contain medications given 
to an infant. Umbilical cord may 
eventually supplant meconium 
as the specimen of choice.  
Due to the potential clinical 
and social work consequences 
associated with a positive test 
result, it is imperative that con-
firmatory drug testing be used 
for definitive identification.2-3 
Many clinical laboratories use an 
initial screening test (typically 
an immunoassay) for drug test-
ing. Screening tests preliminarily 
identify the presence or absence 
of a class of drugs (e.g., opiates). 
However, there are a number of 
possible drugs that can cause 
opiates positive screen (e.g., 
codeine, morphine, heroin). 
Screening tests can also have 
false positives. Confirmatory 
testing typically uses mass spec-
trometry (often in techniques 
like gas chromatography, GC/
MS, or liquid chromatography 
tandem mass spectrometry, 
LC/MS/MS) and can specifically 
identify exact compounds. For 
example, an opiates positive 
specimen can be demonstrated 
by confirmatory testing to have 
codeine and morphine.
Detecting maternal prescrip-
tion drug abuse by newborn 
drug screening
The single biggest challenge in 
identifying prescription drug 
abuse in pregnancy by drug 
testing is separating out mis-
use from other causes such as 
dietary poppy seeds, legitimate 
maternal prescriptions, or 
medications given to mother 
or infant in the peripartum pe-
riod.2-3 Oxycodone, codeine, and 
morphine may be prescribed in 
pregnancy. Morphine may be 
administered to neonates prior 
to meconium collection. Poppy 
seeds also contain morphine 
and/or codeine. Further com-
plicating the picture is that the 
metabolism (breakdown) of opi-
ates in the body is complex (Fig-
ure 1 and Table 1). Certain com-
pounds (e.g., hydromorphone) 
can be given as therapeutic 
agents, but are also known me-
tabolites of other drugs in the 
pathway.
Interpretation of drug test results 
can be difficult. For example, 
detection of morphine in meco-
nium or newborn urine could be 
from iatrogenic administration 
of morphine to mother or new-
born, poppy seed ingestion by 
mother, or as a metabolite of co-
deine.  Detection of oxycodone, 
codeine, or heroin (or its unique 
metabolite 6-monoacetylmor-
phine) in a sample is diagnostic 
of use of these compounds as 
they are not metabolites of any 
other opiates.
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These challenges underscore 
the importance of thorough ma-
ternal and newborn medication 
review. Failure on the part of the 
clinical team to recognize or col-
lect such information could lead 
to inappropriate involvement by 
law enforcement or child pro-
tective services, as well as un-
told stress for the infant’s family. 
In some cases, the drug testing 
results may be compelling but 
not clear-cut enough for definite 
conclusion of drug abuse by the 
mother.
Key points:
• Consider prescription opioid 
abuse in pregnancy.
• Recognize opioids commonly 
used in pregnancy and in the 
perinatal period for mother and 
infant.
• In cases of suspected prescrip-
tion drug abuse in pregnancy, 
obtain a thorough maternal pre-
scription drug history. This may 
necessitate obtaining medical 
records from other hospitals or 
pharmacies.
• Urine, meconium, and um-
bilical cord drug testing of new-
borns may pick up opioids from 
legitimate prescriptions and 
from poppy seeds in the diet.
• Confirmatory drug testing 
should be performed in cases of 
suspected maternal drug abuse 
in pregnancy. Screening drug 
tests on their own may have 
false positives or incomplete in-
formation.
• Utilize the metabolism path-
ways of opiates and benzodiaze-
pines in interpreting drug abuse 
testing.
References:
1. Manchikanti L, Helm S, 2nd, Fellows B, et al. “Opioid epidemic in 
the United States.” Pain Physician. Jul 2012; 15(3 Suppl):ES9-38.
2. Kuczkowski KM. “The effects of drug abuse on pregnancy.” Curr 
Opin Obstet Gynecol. Dec 2007; 19(6):578-585.
3. Montgomery D, Plate C, Alder SC, Jones M, Jones J, Christensen RD. 
“Testing for fetal exposure to illicit drugs using umbilical cord tissue 
vs. meconium.” J Perinatol. Jan 1 2006; 26(1):11-14.
Table 1
Common Opioids and its Major and Minor Metabolites
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*  Not metabolites of any opioids.
**  Detection of either heroin or 6-monoacetylmorphine
 is diagnostic of heroin use.
* Heroin is illegal in the United States. Presence of 6-monoacetylmorphine is 
diagnostic of heroin use
** Drug may be legally prescribed in United States
Detecting Prescription Opioid Abuse in 
Pregnancy            (continued from page 2)
Figure 1
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Perinatal illicit drug use 
and in utero exposure to 
illicit drugs have been 
significant public health 
issues because of the as-
sociated medical, social, 
psychological, and legal 
consequences. It was re-
ported that among preg-
nant women ages 15-44 
years, 5% used illicit drugs 
in 2010-2011 in the United 
States. Other studies at urban 
hospitals have found that ma-
ternal illicit drug use during 
pregnancy ranges from 9-45% 
of all births.1-2 Because of ma-
ternal illicit drug use, 7-11% 
of infants born in the United 
States may be victimized by 
intrauterine drug exposure.2 
In Iowa, children exposed to 
illicit drugs either prenatally 
or postnatally compose the 
fastest growing population of 
children reported for abuse 
and neglect, quadrupling 
from 2000 to 2006 (2.4% in 
2000, 9.4% in 2006). The cur-
rent rates of approximately 
5% do not reflect the actual 
proportion of drug exposed 
children in Iowa since Child 
Protection Services changed 
the criteria under which chil-
dren are to be tested for illicit 
drugs since 2007.
Perinatal Illicit Substance Exposure
and the Dilemma Related to Prescription Abuse 
Resmiye Oral, MD, Director
University of Iowa Children’s Hospital Child Protection Program
 
Illicit drug use has a wide 
spectrum of effects on fetuses 
and children such as low birth 
weight, intrauterine growth 
retardation, prematurity, 
microcephaly and some 
congenital malformations.2 
More importantly, infants 
born to mothers abusing 
drugs during pregnancy are 
often subjected to further 
drug exposure in their home 
environments, child abuse 
and neglect, and domestic 
violence.
The best approach to identify 
perinatal illicit drug exposure 
is to recognize the risk factors 
associated with it as early as 
possible during pregnancy via 
maternal interview and urine/
hair toxicology testing of the 
mothers.2 If the mother refuses 
to be tested, testing the 
newborn via meconium 
and/or umbilical cord 
tissue may be an option.
However, by the time the 
infant tests positive for 
illicit drugs, indicating 
in utero exposure, it is 
often too late to provide 
the mother and the 
newborn with the most 
opportune interventional 
services. It was earlier reported 
that utilization of a structured 
screening protocol increased 
the number of neonatal testing 
for illicit drugs and positive 
testing rate. However, a study 
performed at the University 
of Iowa Hospitals and Clinics 
(UIHC) revealed that the 
adoption of a structured 
protocol did not ensure that 
the staff would necessarily 
utilize it unless a structured, 
staff training program on the 
proper use of the protocol is 
also implemented.3 As a result 
of these observations, the 
UIHC Child Protection Program 
collaborated with the Iowa 
Perinatal Care Program and 
developed a new structured 
protocol that was adopted by 
multiple birthing hospitals as 
well as the UIHC in 2007.
(continues on page 5)




the Labor and Delivery Unit; 
and a third to staff in the 
Mother/Baby and Neonatal 
Intensive Care Units. After 
watching the training videos 
all staff had to complete a 
posttest composed of 10 
questions. Staff needed to 
correctly answer eight of 
the 10 questions in order 
to receive their certificate 
of completion of this 
mandatory training.  
 Documentation of 
posttest results was kept 
by the leading author to 
ensure all staff completed 
the necessary training 
requirements. The training 
of all staff in the above 
listed units was completed 
between July 1, 2007 and 
December 31, 2008. 
2 The charts of dyads 
consisting of mothers and 
their newborn offspring 
receiving pregnancy, 
delivery, and/or newborn 
services at the UIHC were 
reviewed. Data was collected 
in two groups selected on 
the following basis:
a Pre-training control group 
(Pre-TG): All mother-infant 
dyads (n=1,186) admitted 
to the UIHC through 
Obstetrics and Prenatal 
Clinic, Labor and Delivery 
Unit, Mother/Baby Unit, 
or the Neonatal Intensive 
Care Unit between January 
1, 2006 and December 
31, 2006 constituted the 
control group for this study. 
The data collection on 
this group was performed 
Perinatal Illicit Substance Exposure   
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Risk Assessment Tool 
(See Insert, page 6)
The use of this protocol and 
risk assessment tool led to very 
positive results at the UIHC. 
1 The risk assessment tool 
was made part of the online 
documentation system at the 
UIHC, thus, every pregnant 
or delivering woman and 
newborn was screened 
routinely. Associated with 
the new structured protocol, 
the leaders of the program 
developed a training module 
to educate the staff on the 
importance of complying 
with the protocol and how 
to use it. Staff from the 
following departments 
and units were trained to 
utilize the training modules 
and the new protocol, and 
to become trainers for 
their unit staff: Prenatal 
Clinic, Labor & Delivery 
Unit, Mother & Baby Unit, 
Neonatal Intensive Care Unit, 
Department of Psychiatry, 
Chemical Dependency Unit, 
and Department of Social 
Services. The trainers trained 
all relevant unit staff under 
their supervision. 
 This training module 
consisted of three separate, 
unit-specific, in-service 
training video clips. One 
video was presented to staff 
involved in obstetrical and 
prenatal care in the Prenatal 
Clinic; another to staff in 
as part of a previous 
descriptive study by review 
of handwritten charts and 
an early version of UIHC 
online charting system.3  
b Post-training intervention 
group (Post-TG): All 
mother-infant dyads 
(n=1,855) admitted to the 
UIHC through Obstetrics 
and Prenatal Clinic, 
Labor and Delivery Unit, 
Mother/Baby Unit, or the 
Neonatal Intensive Care 
Unit between January 1, 
2009 and December 31, 
2009 constituted the study 
group. Data collection on 
this group was completed 
by review of the online 
UIHC charting system that 
was developed as a part of 
the intervention. 
3 As a result of the 
intervention, significant 
positive developments 
occurred in multiple areas 
related to perinatal illicit 
drug use and exposure. It is 
hoped that every hospital 
providing prenatal care, 
labor and delivery, and 
newborn care services would 
adopt this protocol as soon 
as possible coupled with 
developing a staff training 
program to get the best 
benefits out of this program. 
(See Table 1, page 7)




UIHC Perinatal Illicit Drug/Exposure
RISK ASSESSMENT TOOl
Obstetrics Clinic and labor and Delivery Unit
► Risk Factors Related to Current Pregnancy
Maternal urine drug screen positive  . . . . . . . . . .Yes . . . No
Maternal report of illicit drug use . . . . . . . . . . . . .Yes . . . No
No prenatal care or late prenatal care
 (> 16 weeks gestation) . . . . . . . . . . . . . . . . . . . .Yes . . . No
Unexplained poor prenatal care
 (≤ 4 prenatal visits)  . . . . . . . . . . . . . . . . . . . . . . .Yes . . . No
Unexplained abruptio placenta . . . . . . . . . . . . . . .Yes . . . No
Unexplained premature delivery  . . . . . . . . . . . . .Yes . . . No
Unanticipated out-of-hospital delivery. . . . . . . .Yes . . . No
Unexplained discrepancy between delivery/
 prenatal care facilities (hospital hopping) . .Yes . . . No
Unexplained presentation at hospital in 
 second stage of labor . . . . . . . . . . . . . . . . . . . . .Yes . . . No
Unexplained precipitous labor (<3 hours) . . . . .Yes . . . No
Unexplained episode of acute hypertension 
 (≥140/90 mmHg . . . . . . . . . . . . . . . . . . . . . . . . . .Yes . . . No
Unexplained seizures, stroke, or myocardial 
 infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Yes . . . No
Tobacco or alcohol use . . . . . . . . . . . . . . . . . . . . . . .Yes . . . No
Physical attributes suggesting illicit drug use 
 such as IV track marks, visible tooth decay, 
 sores on face, arms, or legs . . . . . . . . . . . . . . . .Yes . . . No
Altered mental status suggesting influence/
 withdrawal from illicit drugs  . . . . . . . . . . . . . .Yes . . . No
Unexplained stillbirth . . . . . . . . . . . . . . . . . . . . . . . .Yes . . . No
► Risk Factors Related to Maternal Medical History
Unexplained Hepatitis B or C, syphilis, or HIV within the last 
 3 years  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Yes . . .No
Untreated maternal depression or major psychiatric illness 
 within the last 3 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Yes . . .No
Ever used illegal drugs during any pregnancy . . . . . . . . . . . . . . . . Yes . . .No   
Ever delivered an infant who tested positive for illicit drugs. . . Yes . . .No
     
► Risk Factors Related to Maternal/Family Social History
History of illicit drug use by mother or partner within the last 
 3 years  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Yes . . .No
History of illicit drug rehabilitation by mother or partner 
 within the last 3 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Yes . . .No
History of domestic violence by partner within the last 
 3 years  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Yes . . .No
History of child abuse, neglect, or court ordered placement 
 of children outside of  home of this patient . . . . . . . . . . . . . . . Yes . . .No
► If any of these questions are answered with YES, 
 the following should be done:
o Request informed consent from the mother to order urine screening 
for illicit drugs
o Contact the unit social worker to initiate detailed psychosocial 
assessment 
o Request Chemical Dependency Services consult if the social worker 
and the physician believe it is warranted
o Request Psychiatry consult if mental health problems recognized
o Communicate the risk status with Newborn Nursery or NICU staff 
verbally (for L&D staff)
o Attach copy of this form to Labor and Delivery Form and send to the 
Newborn Nursery or NICU along with the baby
 
Newborn Nursery/NICU Bays 1-4 
► Risk Factors Related to Newborn Assessment
Maternal risk factor(s) present . . . . . . . . . . . . Yes. . . No
Mother was tested during this pregnancy 
 or labor for illicit drugs . . . . . . . . . . . . . . . . Yes. . . No
Mother tested positive for illicit drugs 
 during this pregnancy  . . . . . . . . . . . . . . . . Yes. . . No
Gestation ≤37 weeks from unexplained 
 preterm delivery . . . . . . . . . . . . . . . . . . . . . . Yes. . . No
Unexplained birth weight less than 10th 
 percentile for gestational age  . . . . . . . . . Yes. . . No
Unexplained head circumference less than
 10th percentile for gestational age . . . . . Yes . . No
Unexplained seizures, stroke, or brain infarction . . . . . . . . .Yes . . .No
Unexplained symptoms that may suggest drug withdrawal/
intoxication: high-pitched cry, irritability, hypertonia, 
 lethargy, disorganized sleep, sneezing, hiccoughs, 
 drooling, diarrhea, feeding problems, or
 respiratory distress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Yes . . .No    
Unexplained congenital malformations involving 
 genitourinary tract, abdominal wall, or 
 gastrointestinal systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Yes . . .No
► Staff should order meconium and urine screening tests for 
illicit drugs if the answer is Yes to one or more questions under 
the Maternal or Infant Risk Assessment Tool.
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Table 1: Comparison of Pre-TG (2006) and Post-TG (2009) dyads’ variables (n,(%))
Pre-TG Post-TG P value
Maternal drug testing performed  73 (6.2) 300 (16.1) <0.001
Maternal positive drug testing 15 (1.3) 69 (3.7) <0.001
Social worker involved in case 87 (7.3) 610 (32.8) <0.001
Maternal referral for substance abuse evaluation 8 (0.7) 39 (2.1) 0.002
Maternal referral for substance abuse treatment 8 (0.8) 13 (0.7) 0.760
Maternal referral to mental health evaluation 89 (7.6) 259 (19.1) <0.001
Maternal mental health treatment 87 (7.4) 310 (23.8) <0.001
Infant drug test performed 144 (12.3) 554 (30.1) <0.001
Positive infant drug test 11 (0.9) 127 (6.9) <0.001
Missed opportunities for testing infants 248 (20.9) 10 (0.6) <0.001
Pre-TG: Pre-training group                            Post-TG: Post-training group              
NA: Not applicable since substance abuse treatment took place outside of the study institution for those who 
were referred for treatment.    
 
References:
1. Ostrea EM, Brady M, 
Gause S, Raymundo AL, 
Stevens M. “Drug screening 
of newborns by meconium 
analysis: a large-scale, 
prospective, epidemiologic 
study.” Pediatrics. 1992 Jan; 
89(1):107-13.
2. Bauer CR, Shankaran S, 
Bada HS, Lester B, Wright 
LL, Krause-Steinrauf H, et 
al. “The Maternal Lifestyle 
Study: drug exposure during 
pregnancy and short-term 
maternal outcomes.” Am J 
Obstet Gynecol. 2002 Mar; 
186(3):487-95.
3. Oral R, Koc F, Bayman EO, 
Assad A, Austin A, Strang T, 
Bayman L. “Perinatal illicit 
drug screening practices in 
mother-newborn dyads at a 
university hospital serving 
rural/semi-urban communities: 
translation of research to 
quality improvement.” J Matern 
Fetal Neonatal Med. 2012; 
25(11):2441-6.
Perinatal Illicit Substance Exposure   
(continued from page 5)
 EPSDT Care for Kids Newsletter    Fall 2013    http://www.iowaepsdt.org/EPSDTNews/  
The  EPSDT Care for Kids Newsletter  is published 
three times a year, in print and online, as a joint 
effort of the Iowa Prevention of Disabilities Policy 
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to provide them with information about a wide 
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